Yin et al. [98] developed a dual-targeting liposomal codelivery system (T12/P-Lipo) modified with a transferrin receptor TfR-binding peptide (T12) to enhance BBB penetration and an anti-PD-L1 nanobody to target TAM and BM of EGFR T790M-mutated NSCLC. Here, TFRC is linked to non-small cell lung carcinoma.